Biostage, Inc. BSTG
We take great care to ensure that the data presented and summarized in this overview for Biostage, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BSTG
Top Purchases
Top Sells
About BSTG
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company is engaged in developing Biostage Esophageal Implant for the treating esophageal cancer. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.
Insider Transactions at BSTG
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 27
2024
|
Junli He CEO |
BUY
Open market or private purchase
|
Direct |
5,101
+1.93%
|
$15,303
$3.37 P/Share
|
|
Jun 21
2024
|
Junli He CEO |
BUY
Open market or private purchase
|
Direct |
1,600
+0.62%
|
$3,200
$2.8 P/Share
|
|
Dec 27
2023
|
Junli He CEO |
BUY
Open market or private purchase
|
Direct |
2,700
+1.06%
|
$10,800
$4.76 P/Share
|
|
Dec 14
2023
|
Junli He CEO |
BUY
Open market or private purchase
|
Direct |
900
+0.36%
|
$3,600
$4.92 P/Share
|
|
Dec 06
2023
|
Junli He CEO |
BUY
Open market or private purchase
|
Direct |
1,500
+0.6%
|
$7,500
$5.07 P/Share
|
|
Sep 11
2023
|
Junli He CEO |
BUY
Open market or private purchase
|
Direct |
1,500
+0.6%
|
$7,500
$5.43 P/Share
|
|
Aug 28
2023
|
Junli He CEO |
BUY
Open market or private purchase
|
Direct |
3,400
+1.36%
|
$13,600
$4.69 P/Share
|
|
Aug 21
2023
|
James E. Shmerling Director |
BUY
Open market or private purchase
|
Direct |
6,864
+22.42%
|
$27,456
$4.35 P/Share
|
|
Aug 18
2023
|
Junli He CEO |
BUY
Open market or private purchase
|
Direct |
8,000
+3.19%
|
$32,000
$4.32 P/Share
|
|
Apr 06
2023
|
Dst Capital LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
62,500
+1.65%
|
$375,000
$6.0 P/Share
|
|
Dec 12
2022
|
Junli He CEO |
SELL
Open market or private sale
|
Direct |
135
-0.06%
|
$810
$6.83 P/Share
|
|
Dec 07
2022
|
Dst Capital LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,952
-0.05%
|
$13,664
$7.17 P/Share
|
|
Dec 07
2022
|
Dst Capital LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
7,000
+0.19%
|
$14,000
$2.0 P/Share
|
|
Dec 07
2022
|
Hong Yu PRESIDENT |
SELL
Open market or private sale
|
Indirect |
83,676
-27.33%
|
$585,732
$7.17 P/Share
|
|
Dec 07
2022
|
Hong Yu PRESIDENT |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
300,000
+49.49%
|
$600,000
$2.0 P/Share
|
|
Dec 07
2022
|
Jing Chen Director |
SELL
Open market or private sale
|
Direct |
48,532
-23.11%
|
$339,724
$7.17 P/Share
|
|
Dec 07
2022
|
Jing Chen Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
174,000
+45.31%
|
$348,000
$2.0 P/Share
|
|
May 12
2022
|
David Green Director |
BUY
Open market or private purchase
|
Direct |
63,345
+28.51%
|
$316,725
$5.92 P/Share
|
|
May 12
2022
|
James E. Shmerling Director |
BUY
Open market or private purchase
|
Direct |
16,892
+50.0%
|
$84,460
$5.92 P/Share
|
|
May 12
2022
|
Dst Capital LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
8,277
+0.23%
|
$41,385
$5.92 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 11.8K shares |
|---|